Vioxx: lessons for Health Canada and the FDA
- Vioxx. // Formulary;May2004, Vol. 39 Issue 5, p235
Provides information on Merck & Co. Inc.'s cyclooxygenase-2 inhibitor Vioxx, or rofecoxib, which has been approved by the U.S. Food and Drug Administration for the treatment of migraine. Mechanism of action; Drug efficacy; Safety; Dosing.
- FDA requests further data on Merck's Arcoxia application. // PharmaWatch: CNS;December2004, Vol. 3 Issue 12, p16
Reports that the U.S. Food and Drug Administration has informed Merck & Co. that it will require further safety and efficacy information before granting approval of Merck's new drug application for the COX-2 inhibitor, Arcoxia. Company's revision of its new drug application to the agency to...
- Blow for Merck as FDA rejects Arcoxia. // TCE: The Chemical Engineer;May2007, Issue 791, p5
The article reports that an advisory committee to the U.S. Food and Drug Administration (FDA) has recommended that Merck's cyclooxygenase-2 inhibitor, Etoricoxib, should not be approved. The committee pointed out that the risks associated with the drug, commonly known as Arcoxia, outweigh its...
- Out of sight. McLaughlin, Neil // Modern Healthcare;10/18/2004, Vol. 34 Issue 42, p26
Focuses on the problems facing the pharmaceutical industry in the U.S. Recall of Vioxx cyclooxygenase 2 inhibitor by Merck & Co.; Flu vaccine debacle; Emergence of reports on price gouging.
- Vioxx withdrawal spurs rivals into action. McGuire, Stephen // Medical Marketing & Media;Nov2004, Vol. 39 Issue 11, p12
This article reports that in the wake of Merck & Co. Inc.'s decision to withdraw Vioxx because of unfavorable clinical trials data, Pfizer and Boehringer Ingelheim/ Abbot Laboratories' stepped up efforts to promote their respective rival COX- 2 inhibitors, Celebrex and Mobic. Merck had pulled...
- Will the FDA's axe fall on COX-2s? // PharmaWatch: Monthly Review;Feb2005, Vol. 4 Issue 2, p23
The article reports on the effects of the controversies about the cardiovascular dangers of cyclooxygenase-2 inhibitors on the pharmaceutical industry. The withdrawal of Merck & Co.'s Vioxx from the market because of these concerns has brought shockwaves in the sector. Pfizer Inc. has also...
- Courts spell further trouble for COX-2. Houlton, Sarah // European Pharmaceutical Executive;Nov/Dec2005, p6
The article discusses court cases faced by pharmaceutical companies manufacturing COX-2 inhibitors. A woman in Texas was compensated by Merck & Co. Inc. due to the death of her husband allegedly from Vioxx side-effects. A second legal battle is under way in New Jersey. Merck claims that it can...
- Merck s Loss Could Turn Out to be Pfizer's Gain. // Chemical Market Reporter;10/11/2004, Vol. 266 Issue 12, p12
Reports that Merck & Co.'s recall of the drug Vioxx (rofecoxib), a Cox-2 inhibitor, could actually boost the revenue at Pfizer Inc.. Confidence that patients will not abandon Cox-2 inhibitor drugs completely; Pfizer's competing Cox-2 inhibitors, Celebrex and Bextra; Patient safety concerns
- The Impact of Vioxx on US drug regulation. // Reactions Weekly;12/3/2005, Issue 1080, p2
The article discusses research being done on the impact Merck & Co's Vioxx on U.S. drug regulations. It references a study by T. Zwillich published in the November 19, 2005 issue of "Lancet." Merck & Co.'s COX-2 inhibitor Vioxx has been accused of resulting to a myocardial infarction or...